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Intracavernous Drug Delivery System: An Alternative to 
Intracavernous Injection in the Treatment of Impotence? 
CG. Stief\ U. Wetterauer*, F. Kulvelish, G. Popkenb, J. Staubesandh, H. Sommerkamp* 
a Department of Urology and b Institute of Anatomy, University of Freiburg, FRG 
Key Words. Erection · Intracavernous injection · Drug delivery system · Cavernous fibrosis 
Abstract. In 6 monkeys, the feasibility of chronic intracavernous drug application via a permanent intracavernous 
catheter was examined. In 4 monkeys, a combination of papaverine (15 mg/ml) and phentolamine (0.5 mg/ml) was 
injected via the drug delivery system; in 2 monkeys each, 30 or 100 injections were done. As a control, saline was 
injected in 2 monkeys. The dose of the papaverine-phentolamine mixture to induce full erection had to be increased 
by a mean of 240%, comparing the 1st to the 30th injection. The dose then remained stable. After 100 injections, 
penile histology showed a thin fibrotic layer around the implantation site of the catheter. Beside slight smooth muscle 
hypertrophy in the papaverine-phentolamine group, there were no abnormal findings in the proximal and medial 
part of the cavernous bodies. The distal part of the cavernous bodies showed extensive fibrosis due to mechanical 
irritation by the tip of the intracavernous catheter. Given appropriate selection and indication, implantation of an 
intracavernous drug delivery system may be an alternative to chronic intracavernous injection in the treatment of 
impotence. 
Introduction 
Within a few years after its first description [1, 2], 
intracavernous injection of vasoactive drugs became a 
standard therapy in the treatment of erectile dysfunc­
tion. Under the condition of careful patient selection 
and close follow-up [3-9] many studies showed this ther­
apeutic option to be efficient and relatively safe. With an 
increasing number of both treated patients and applied 
injections per patient, cavernous fibrosis due to intra­
cavernous (auto)injections were increasingly reported 
[10-14]. 
Recent studies in monkeys [15, 16] showed that the 
cavernous fibrosis is not only caused by the injected 
drug(s) itself, but also by the repeated trauma of the cav­
ernous tissue by the puncture. An implantable drug 
delivery system into the cavernous bodies could be an 
alternative method of intracavernous drug administra­
tion without the need for repeated intracavernous injec­
tions. 
The aim of our study was to evaluate the feasibility of 
intracavernous drug administration via an implantable 
drug delivery system in the treatment of erectile dysfunc­
tion. 
Material and Methods 
Seven Sinomolgus monkeys weighing 5.2-8.7 kg were used for 
the study. After adequate anesthesia with ketamine (6 mg/kg body 
weight i.m.), the monkeys were placed in supine position. From an 
infrapubic incision, the drug port (Implantofix A, Braun Melsun­
gen, Melsungen, FRG) was placed subcutaneously in the lower 
right abdominal quadrant (fig. 1). For intracavernous delivery, an 
intra-arterial catheter with a valved tip (No. 443953/1, Braun Mel­
sungen) was chosen. After careful dissection, the right cavernous 
body was opened proximally between the dorsal vein and the right 
dorsal artery. To prevent slipping out of the cavernous body, the 
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Fig. 1. From an infrapubic approach, the drug port was placed in 
the lower right abdominal quadrant. 
length of the intracavernous catheter was 3-4 cm. The tunica albu-
ginea was closed using a watertight technique. The catheter length 
was then adjusted and the catheter connected to the drug port. The 
dead space of the complete system was less than 0.25 cm 3. For 
injection into the port, 22-gauge Huber needles (that do not destroy 
the membrane of the port by the puncture; Braun Melsungen) were 
used. 
Two monkeys presented postoperative wound infection. After 
removal of the drug delivery system and adequate conservative ther­
apy, another drug delivery system could be implanted. One of these 
2 monkeys was finally excluded from the study after scratching out 
the second drug delivery system. Before the implantation, drug port 
and catheter were filled with heparinized saline. Two weeks postop­
eratively, a standardized solution of papaverine (15mg/ml) and 
phentolamine (0.5 mg/ml) was injected transcutaneously into the 
drug port 3 times a week in 4 monkeys, followed each time by a flush 
of 0.5 cm 3 heparinized saline. The injected dose was chosen depen­
dent on the previous erectile response; a full erection of at least 
30 min was projected. The initial dose was 0.4 ml, the mean dose 
after 30 injections was 1.02 ml. To minimize possible systemic side 
effects, the maximal dose was set to be 1.6 ml. Two monkeys were 
sacrificed after 30 and 2 after 100 injections. Al l injections were 
done under ketamine anesthesia. The erectile response was moni­
tored by a urologist by inspection and palpation. 
Two monkeys served as controls. They were injected heparin­
ized saline alone, following the above-mentioned injection protocol. 
They were sacrificed after 100 injections. 
Results 
Beside the above-mentioned wound infections in 2/7 
monkeys, no major surgical complications were ob­
served. In 1 monkey, 2 episodes of tachycardia occurred 
after injection of 2 ml of the papaverine-phentolamine 
mixture. One monkey died of laryngospasm shortly after 
intramuscular ketamine injection (88 injections of pa­
paverine-phentolamine). 
Comparing the 1st to the 30st injection, the amount 
of the papaverine-phentolamine mixture increased from 
a mean of 0.3 to 1.02 ml (240%). The dose to induce full 
erection then remained relatively constant during the 
study (fig. 2). No monkey developed priapism, the max­
imal duration of full erection was 80 min. 
After 30 injections of the vasoactive drug mixture, 2 
monkeys were sacrificed. With the exception of the tip of 
the penis, the cavernous bodies did not reveal significant 
signs of localized or generalized fibrosis on palpation. 
Histology showed a thin fibrotic layer around the im­
plantation site of the catheter. In the proximal and 
medial part of the cavernous bodies, the cavernous tissue 
surrounding the implantation site showed only scattered, 
nonsignificant increase in collagen (fibrous tissue; 
fig. 3a, b). In the distal part of the cavernous body, where 
the valved tip of the catheter filled almost the complete 
cavernous body, histology showed extensive replace­
ment of cavernous smooth muscles by fibrous tissue. 
Here, multiple areas with hemosiderosis were found 
(fig. 4). 
After 100 and 88 injections, respectively, the mon­
keys of the papaverine and phentolamine group were 
sacrificed. In addition, after 100 injections, the 2 mon­
keys in the saline control group were sacrificed. In both 
groups, palpation of the cavernous bodies suggested 
fibrosis of the distal part. Histologic examination 
showed similar findings in the saline and the papaverine-
phentolamine groups. The implantation site of the cath­
eter was surrounded by a thin fibrous sheath. This 
fibrous sheath showed no intraluminal protrusions in 
any sections. In the proximal and medial part of the 
penis, cavernous tissue showed no significant increase in 
collagen, whereas cavernous smooth muscles of the dis­
tal port were widely replaced by fibrous tissue. Caver-
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b 
Fig. 3. a In the proximal and medial part of the cavernous bodies, the cavernous tissue of the saline group showed no abnormal findings. 
The cavernous sinusoids were partially filled with erythrocytes. X 75. b In the proximal and medial part of the cavernous bodies, the 
cavernous tissue showed no fibrotic changes. The cavernous smooth muscles showed slight smooth muscle hypertrophy i f compared to 
figure 3a. Note the arteriovenous anastomosis (arrow). X 75. 
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Fig. 4. The fibrous sheath around the implantation site of the 
catheter is seen at the bottom, the tunica albuginea at the top of the 
figure. In all monkeys, the distal part of the cavernous bodies 
showed extensive fibrosis with few cavernous sinusoids left. The 
fibrous tissue showed hemosiderosis (dark dots) as a sign of chronic 
microtrauma with consecutive hemorrhage. X 150. 
nous smooth muscles in the papaverine-phentolamine 
group showed a slight but evident hypertrophy com­
pared to the saline group (compare fig. 3a and 3b). 
Discussion 
Our results show that at the implantation site of an 
intracavernous drug delivery system a thin fibrotic layer 
is formed by the cavernous tissue. It can be assumed that 
this fibrotic sheath was responsible for the need for aug­
mentation of the dose of the papaverine-phentolamine 
mixture to constantly induce full erection. This phase of 
continous augmentation lasted until about the 30th in­
jection (about 3 months). The dose to induce full erec­
tion then remained rather constant (fig. 2). This stable 
erectile response is probably due to an unchanged diffu­
sion pattern for the vasoactive mixture of the fibrous 
sheath between the 30th and the 100th injection, i.e. the 
3rd and the 9th month. The question i f the permeability 
of the fibrous sheath will remain stable or further decline 
over a longer period of time cannot be answered by our 
study. 
The assumption of a comparable fibrotic sheath 
around the catheter after 30 compared to 100 injections 
was supported by our histological findings. There was 
equal thickness of the fibrous sheets after 30 and 100 
injections. Beside the fibrous sheath around the implan­
tation site, no significant changes of the cavernous tissue 
were found in the proximal and medial part of the 
penis. 
The assumption of a comparable fibrotic sheath 
around the catheter after 30 compared to 100 injections 
was supported by our histological findings. There was 
equal thickness of the fibrous sheet after 30 and 100 
injections. Beside the fibrous heath around the implanta­
tion site, no significant changes of the cavernous tissue 
were found in the proximal and medial part of the 
penis. 
Comparing the papaverine-phentolamine group to 
the saline group, we found discrete smooth muscle hy­
pertrophy in the first. There is a dramatic difference 
comparing the slight cavernous smooth muscle hypertro­
phy to papaverine-phentolamine in our study and the 
extensive smooth muscle hypertrophy to papaverine 
alone [15, 16]. Although the monkey species used in the 
studies are different, the results are likely to be compara­
ble because of a similar penile size and an identical injec­
tion protocol. The reason for the evident histologic dif­
ference between the study of Abozeid et al. [ 15] and Abo-
seif et al. [16] and ours is speculative, since there are still 
extensive gaps in our understanding of basic smooth 
muscle physiology. It seems that there is a significant 
difference in cavernous smooth muscle relaxation by 
papaverine (direct smooth muscle relaxant) and phentol­
amine (alpha receptor blocker and therefore acting by 
reduction of the sympathetic tone) on the cellular and/or 
subcellular level, thus inducing extensive smooth muscle 
hypertrophy in one and not in the other case. 
Histology of the distal part of the cavernous body 
showed extensive fibrosis. This replacement of smooth 
muscles by fibrous tissue is probably due to the mechan­
ical irritation by the valved catheter tip. At variance with 
the dog and similar to the human, erection of the mon­
key consists of tumescence and rigidity. During tumes­
cence and detumescence, the valved tip slips within the 
cavernous body thus causing fibrous changes. This as-
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sumption is supported by the extensive hemosiderosis in 
the fibrotic cavernous tip as a sign of frequent trauma 
with consecutive microhemorrhage. A further cause of 
the extensive distal fibrosis is the size of the valved cath­
eter tip, that, although relatively small, filled almost the 
whole lumen of the distal cavernous body, therefore 
causing a localized continuous compression of the caver­
nous tissue. 
Desai et al. [ 17] were the first to describe intracaver­
nous implantation of a drug delivery system. It was 
applied in 3 patients with difficulties regarding direct 
intracavernous injections for the treatment of impotence. 
For intracavernous drug delivery, they used a catheter for 
intravenous implantation (without valved tip) with sev­
eral holes at the end of the catheter. After explantation of 
the catheter in 1 patient, histologic examination revealed 
fibrous tissue protruding into the holes at the end of the 
catheter, which caused inacceptably high injection pres­
sures [Desai, K.M.: personal commun.]. In our experi­
mental study, we therefore chose a catheter with valved 
tip (instead of holes). Usually used for intra-arterial im­
plantation, it can withstand the high intracavernous pres­
sures during erection without the risk of retrograde blood 
flow into the catheter. 
Beside the fibrous sheath around the implantation 
site of the catheter, we did not find a significant increase 
in fibrous tissue within the cavernous tissue. Although 
direct comparison with the chronic intracavernous injec­
tion studies [15, 16] is difficult due to different subspe­
cies and different drug application, it seems that the 
addition of phentolamine to papaverine significantly re­
duced cavernous fibrosis compared to the intracaver­
nous injection of papaverine alone [15, 16]. 
Our results show that an intracavernous drug delivery 
system can be used to apply drugs intracavernously over 
a certain period of time. Further long-term studies are 
needed before its application in carefully selected pa­
tients may be considered. In this case, combination with 
a miniature pump with reservoir would be advanta­
geous. 
4 Robinette MA, Moffat MJ: Intracorporal injection of papaver­
ine and phentolamine in the management of impotence. Br J 
Urol 1986;58:692. 
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function: Experience with 100 patients. J Urol 1986; 135:704. 
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for the treatment of impotence. J Urol 1987; 137:678. 
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